Precipio (PRPO) Company Report

Precipio repaid a $1.1 million advance from Change Healthcare in early January 2026, which was provided to cover collections shortfalls due to a 2024 cybersecurity incident.
The company's balance sheet is now debt-free, except for a small loan of approximately $80,000 from the Connecticut Department of Economic and Community Development, payable by May 2028.
All financial warrants issued as part of a 2023 financing were exercised in Q3 and Q4 of 2025, including some cashless exercises, resulting in no further financial warrants outstanding.
10,000 warrants given to a vendor in 2022, with a strike price of $60, remain outstanding and expire in February 2027.

Jan 15, 2026, 2:00 PM

Precipio Reports First-Ever Positive Adjusted EBITDA and Cash from Operations in Q3 2025

PRPO

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

Precipio reported its first-ever positive adjusted EBITDA of nearly $500,000 and generated $285,000 in cash from operations for Q3 2025.
Total revenue for Q3 2025 reached $6.8 million, representing a 30% increase year-over-year and a 20% increase quarter-over-quarter.
The Pathology Services Division's revenue grew to $6 million with its gross margin improving from 43% to 46%, while the Products Division's revenue increased to $720,000 despite a temporary decline in gross margin due to strategic investments.
The company anticipates total gross margins to surpass 50% by mid-2026 and expects to become fully self-sustaining, with $240,000 in quarterly cash flow freed up after completing debt repayments by Q1 2026.

Nov 17, 2025, 10:00 PM

Precipio Reports First-Ever Positive Adjusted EBITDA and Cash from Operations in Q3 2025

PRPO

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

Precipio achieved its first-ever positive adjusted EBITDA of $469,000 and generated $285,000 in cash from operations in Q3 2025, indicating a shift to self-sustainability.
Total revenue for Q3 2025 reached $6.8 million, marking a 30% increase year over year and a 20% increase quarter over quarter.
Both divisions contributed to this growth, with the Pathology Services Division's revenue increasing 20% quarter-over-quarter to $6 million and the Products Division growing 16% quarter-over-quarter to $720,000.
Overall gross margins improved from 43% to 44% in Q3 2025, driven by the Pathology Services Division's margins rising to 46%. The Products Division's gross margins temporarily declined to 30% due to strategic investments in lab space and a new technical support specialist.
The company anticipates total gross margins will exceed 50% by mid-2026 and expects continued double-digit growth in both divisions.

Nov 17, 2025, 10:00 PM

Precipio Achieves First Positive Adjusted EBITDA in Q3 2025

PRPO

Earnings

Revenue Acceleration/Inflection

New Projects/Investments

Precipio achieved its first positive adjusted EBITDA of nearly $500,000 and generated $285,000 in cash from operations in Q3 2025.
Revenue for Q3 2025 reached $6.8 million, representing a 30% increase year-over-year and a 20% increase quarter-over-quarter.
Both the Pathology Services Division and Products Division contributed to growth, with Pathology Services revenue increasing 20% quarter-over-quarter to $6 million and Products Division growing 16% quarter-over-quarter to $720,000.
Overall gross margins improved slightly to 44% in Q3 2025, though Products Division margins temporarily declined to 30% due to strategic investments in lab space and personnel, which are expected to support future revenue growth.
The company anticipates total gross margin to exceed 50% by mid-2026 and is now self-sustaining, no longer reliant on external capital for operations.